Odyssey Therapeutics, Inc. 8-K

What Happened Odyssey Therapeutics, Inc. (ODTX) filed a Current Report on Form 8-K on June 23, 2026 (Item 7.01) announcing that it posted a corporate presentation on its investor relations website. A copy of the presentation was furnished as Exhibit 99.1 to the Form 8-K. The report was signed by Jason Haas, Chief Financial Officer, on June 23, 2026.

Key Details

• Filing date: June 23, 2026.
• Disclosure type: Regulation FD disclosure (Item 7.01).
• Presentation furnished as Exhibit 99.1 to the Form 8-K.
• Posted at: https://investors.odysseytx.com/news-events/presentations.
• Form also includes the standard exhibits filing entry (Item 9.01) and was signed by CFO Jason Haas.

Why It Matters This 8-K lets all investors know Odyssey has made a corporate presentation publicly available under Regulation FD, ensuring the information was broadly distributed rather than given selectively. The filing itself does not report earnings, executive changes, mergers, or financial results — it simply documents the public posting of investor presentation materials that may contain updates on strategy, programs, or operating highlights. Investors who follow Odyssey should review the posted presentation for any new company details.